Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

Sentinel lymph node biopsy for melanoma: an important risk-stratification tool

- Featured Image

This test should be routinely considered for patients with intermediate thickness melanoma

Most patients with a new diagnosis of melanoma present with localised disease without clinical evidence of metastasis and are cured by surgical resection. However, a small proportion will harbour occult metastatic disease in the regional lymph nodes. The presence of nodal involvement is the most significant prognostic factor in patients without clinical evidence of distant metastasis.1 The most sensitive test to identify these patients at presentation is sentinel lymph node biopsy (SLNB).1,2 The sentinel lymph node is the first draining lymph node from the area of skin where the primary tumour arose. The technique was first described over 20 years ago.3 Careful histological examination of the sentinel lymph node by a combination of routine histological and immunohistochemistry tests can accurately identify small-volume metastatic disease.

On the basis of initial reports, SLNB has rapidly become the standard of care in major melanoma centres around the world for patients with melanoma greater than 1 mm in thickness (stage T2 and above; Box 1) and incorporated into the American Joint Committee on Cancer staging system.1

email